115 results
Page 5 of 6
6-K
EX-99.1
h8rx5kb xzf8sf
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am
6-K
EX-99.1
efc2y
17 Aug 20
Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer
7:35am
6-K
EX-99.1
noc lgtwm2k2blm
13 Aug 20
Current report (foreign)
7:30am
6-K
EX-99.1
x4zn8eo
20 Jul 20
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
7:35am
6-K
EX-99.1
l1q8wu 6haw1g17ce
7 Jul 20
Turning Point Therapeutics and Zai Lab Announce
7:35am
6-K
EX-99.1
0diuc1xtnm2hu44382h
13 May 20
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
10:22am
6-K
EX-99.1
wi0kuw7nq68jxtuj2
8 Apr 20
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau
6:03am
6-K
EX-99.1
djk7g eeb
19 Mar 20
Current report (foreign)
7:53am
6-K
EX-99.1
m0m2y qtxrksji1c
16 Mar 20
Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA
7:39am
424B2
zp19 pfpj90b46
24 Jan 20
Prospectus for primary offering
7:24am
424B5
hu4gy2g1
21 Jan 20
Prospectus supplement for primary offering
5:31pm
6-K
EX-99.1
gq81fwq2nw
14 Jan 20
Zai Lab Appoints Lonnie Moulder to Board of Directors
7:30am
6-K
EX-99.1
5f6wmgx
27 Dec 19
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer
7:51am
20-F/A
EX-10.15
grbcys zp9yw
23 Aug 19
Annual report (foreign) (amended)
5:00pm
6-K
EX-99.1
w1ooriu mb3d
2 Jul 19
Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
7:32am
20-F/A
EX-10.15
nvsdhqyd
26 Jun 19
Annual report (foreign) (amended)
6:07am
6-K
EX-99.1
acw5cgq6 k13
11 Jun 19
Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
7:00am